S 16260

Drug Profile

S 16260

Alternative Names: R-60; S-16260-2

Latest Information Update: 31 Mar 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Servier
  • Class Antiarrhythmics
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Arrhythmias

Most Recent Events

  • 02 Sep 1998 No-Development-Reported for Arrhythmias in France (Unknown route)
  • 28 Nov 1995 An In vitro pharmacodynamic study has been added to Arrhythmias
  • 16 Mar 1995 Preclinical development for Arrhythmias in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top